We set up a state-f funded newborn screening program to offer children whole [music] genome sequencing at birth free of charge. So, it's an issue. >> Any parent who wants to put their child into this.>> Yes, it's [music] an opt-in program. So, it involves their consent. >> When you think about Drew, is [music] he forever four years old in your mind or >> Oh, that's a great question.>> [music] >> This is the path. I'm Becky Quick. Thank you for coming back.[music] >> In my 25 years at CNBC reporting on the s ...

Company Overview - Natera is a genetic testing company specializing in detecting tiny quantities of DNA across healthcare areas [3] - The company has a market cap of approximately $22 billion [2] - Natera has processed 12 million tests so far [11] Technology and Products - Natera's technology can detect cancer recurrence up to two years in advance of imaging [4][8] - The company utilizes a unique test called Signatera, specialized for each patient, to detect circulating tumor DNA [5][7] - The test sequences the entire tumor and compares it to the patient's germline DNA to identify unique signatures [7][9] Market and Financials - Natera operates in a total addressable market estimated at $50 billion [12] - The MRD (Minimal Residual Disease) segment, including Signatera, represents a $20 billion market [12] - The company follows standard billing and reimbursement guidelines and is in-network with most insurance plans [10][11]